Shirin Shafazand, MD
Pulmonary Disease · Miami, FLNPI 1225044738
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $191,459 of the $193,175 with a category attached, or 99.1%. AstraZeneca accounts for 77.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $89,695 and has fallen 63.5% since, to $32,715 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $2384.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$150K
- Astrazeneca UK Limited$37K
- Resmed Corp$4K
- Boehringer Ingelheim$2K
- Sunovion Pharmaceuticals Inc.$83
- United Therapeutics Corporation$3
Across 51 payments — averaging $15,315 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$670K
- Boehringer Ingelheim$60K
- Novartis$46K
- Boehringer Ingelheim Pharma GmbH & Co.kg$3K
- Sanofi$2K
What the payments were for
- Consulting fees$191,45999%
- Speaking & faculty fees$1,6311%
- Food & beverage$830%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $149,817 |
| Astrazeneca UK Limited | 16 | $37,178 |
| Resmed Corp | 8 | $4,464 |
| Boehringer Ingelheim | 4 | $1,631 |
| Sunovion Pharmaceuticals Inc. | 4 | $83 |
| United Therapeutics Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$193,175 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 19 | $455,562 |
| Ambrisentan | 101 | $357,585 |
| Sildenafil Citrate | 100 | $24,587 |
| Tadalafil | 33 | $13,653 |
| Pirfenidone | 13 | $9,911 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Raul ValorMiami$232K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Jaime AvecillasMiami$70K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.